HEPATOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗？凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE，投稿一星期了，还是Selecting/Assigning Reviewers，困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投了一篇clinical trial 04/04/2019 Submission 04/05/2019 Selecting/Assigning Reviewers 04/08/2019 Under Review 04/09/2019 Selecting/Assigning Reviewers 04/09/2019 Under Review 04/22/2019 Reviews Returned 05/01/2019 Evaluating Reviews 05/02/2019 Reject with Transfer – HepComm 非常诡异的是，经历了一个月选审稿人又重选审稿人又under review的状态，最后的拒信居然没有外审意见，说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578795, encodeId=ead55e87956f, content=再等等看吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝硬化;预测模型 经验分享：肝病4大顶刊之一，有幸中了一篇。 贡献一个timeline； 07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit 5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投，现在修回去了，但是刚提交几个小时状态就变成了reviews returned，有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：回顾性临床研究 11.18投稿，12.2拒稿 附两个审稿人的审稿意见 编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=)]

2021-12-29 小动量

方法的撰写顺序/逻辑顺序是什么？

168 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗？凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE，投稿一星期了，还是Selecting/Assigning Reviewers，困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投了一篇clinical trial 04/04/2019 Submission 04/05/2019 Selecting/Assigning Reviewers 04/08/2019 Under Review 04/09/2019 Selecting/Assigning Reviewers 04/09/2019 Under Review 04/22/2019 Reviews Returned 05/01/2019 Evaluating Reviews 05/02/2019 Reject with Transfer – HepComm 非常诡异的是，经历了一个月选审稿人又重选审稿人又under review的状态，最后的拒信居然没有外审意见，说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578795, encodeId=ead55e87956f, content=再等等看吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝硬化;预测模型 经验分享：肝病4大顶刊之一，有幸中了一篇。 贡献一个timeline； 07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit 5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投，现在修回去了，但是刚提交几个小时状态就变成了reviews returned，有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：回顾性临床研究 11.18投稿，12.2拒稿 附两个审稿人的审稿意见 编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=)]

2019-10-10 qmac

审稿速度:1.0 | 投稿命中率:25.0
经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志

273 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗？凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE，投稿一星期了，还是Selecting/Assigning Reviewers，困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投了一篇clinical trial 04/04/2019 Submission 04/05/2019 Selecting/Assigning Reviewers 04/08/2019 Under Review 04/09/2019 Selecting/Assigning Reviewers 04/09/2019 Under Review 04/22/2019 Reviews Returned 05/01/2019 Evaluating Reviews 05/02/2019 Reject with Transfer – HepComm 非常诡异的是，经历了一个月选审稿人又重选审稿人又under review的状态，最后的拒信居然没有外审意见，说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578795, encodeId=ead55e87956f, content=再等等看吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝硬化;预测模型 经验分享：肝病4大顶刊之一，有幸中了一篇。 贡献一个timeline； 07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit 5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投，现在修回去了，但是刚提交几个小时状态就变成了reviews returned，有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：回顾性临床研究 11.18投稿，12.2拒稿 附两个审稿人的审稿意见 编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=)]

2019-02-05 半夜吹口哨

请问作者签名确认必须完成才会送审吗？凱凱 2018-02-03 23:24:00 发表:
2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject.
總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.

凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject.
總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.

221 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗？凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE，投稿一星期了，还是Selecting/Assigning Reviewers，困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投了一篇clinical trial 04/04/2019 Submission 04/05/2019 Selecting/Assigning Reviewers 04/08/2019 Under Review 04/09/2019 Selecting/Assigning Reviewers 04/09/2019 Under Review 04/22/2019 Reviews Returned 05/01/2019 Evaluating Reviews 05/02/2019 Reject with Transfer – HepComm 非常诡异的是，经历了一个月选审稿人又重选审稿人又under review的状态，最后的拒信居然没有外审意见，说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578795, encodeId=ead55e87956f, content=再等等看吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝硬化;预测模型 经验分享：肝病4大顶刊之一，有幸中了一篇。 贡献一个timeline； 07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit 5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投，现在修回去了，但是刚提交几个小时状态就变成了reviews returned，有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：回顾性临床研究 11.18投稿，12.2拒稿 附两个审稿人的审稿意见 编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=)]

2019-07-30 liuxd6

显示with DE，投稿一星期了，还是Selecting/Assigning Reviewers，困惑

194 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗？凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE，投稿一星期了，还是Selecting/Assigning Reviewers，困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投了一篇clinical trial 04/04/2019 Submission 04/05/2019 Selecting/Assigning Reviewers 04/08/2019 Under Review 04/09/2019 Selecting/Assigning Reviewers 04/09/2019 Under Review 04/22/2019 Reviews Returned 05/01/2019 Evaluating Reviews 05/02/2019 Reject with Transfer – HepComm 非常诡异的是，经历了一个月选审稿人又重选审稿人又under review的状态，最后的拒信居然没有外审意见，说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578795, encodeId=ead55e87956f, content=再等等看吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝硬化;预测模型 经验分享：肝病4大顶刊之一，有幸中了一篇。 贡献一个timeline； 07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit 5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投，现在修回去了，但是刚提交几个小时状态就变成了reviews returned，有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：回顾性临床研究 11.18投稿，12.2拒稿 附两个审稿人的审稿意见 编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=)]

2021-12-27 rayms

结果中的重要文献是在结果体现，还是在引言中描述？

111 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗？凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE，投稿一星期了，还是Selecting/Assigning Reviewers，困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投了一篇clinical trial 04/04/2019 Submission 04/05/2019 Selecting/Assigning Reviewers 04/08/2019 Under Review 04/09/2019 Selecting/Assigning Reviewers 04/09/2019 Under Review 04/22/2019 Reviews Returned 05/01/2019 Evaluating Reviews 05/02/2019 Reject with Transfer – HepComm 非常诡异的是，经历了一个月选审稿人又重选审稿人又under review的状态，最后的拒信居然没有外审意见，说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578795, encodeId=ead55e87956f, content=再等等看吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝硬化;预测模型 经验分享：肝病4大顶刊之一，有幸中了一篇。 贡献一个timeline； 07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit 5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投，现在修回去了，但是刚提交几个小时状态就变成了reviews returned，有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：回顾性临床研究 11.18投稿，12.2拒稿 附两个审稿人的审稿意见 编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=)]

2019-05-03 Cure

审稿速度:1.0 | 投稿命中率:5.0
经验分享：投了一篇clinical trial
04/04/2019 Submission
04/05/2019 Selecting/Assigning Reviewers
04/08/2019 Under Review
04/09/2019 Selecting/Assigning Reviewers
04/09/2019 Under Review
04/22/2019 Reviews Returned
05/01/2019 Evaluating Reviews
05/02/2019 Reject with Transfer – HepComm
非常诡异的是，经历了一个月选审稿人又重选审稿人又under review的状态，最后的拒信居然没有外审意见，说内部编辑觉得不合适直接拒的。已写信询问。

243 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗？凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE，投稿一星期了，还是Selecting/Assigning Reviewers，困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投了一篇clinical trial 04/04/2019 Submission 04/05/2019 Selecting/Assigning Reviewers 04/08/2019 Under Review 04/09/2019 Selecting/Assigning Reviewers 04/09/2019 Under Review 04/22/2019 Reviews Returned 05/01/2019 Evaluating Reviews 05/02/2019 Reject with Transfer – HepComm 非常诡异的是，经历了一个月选审稿人又重选审稿人又under review的状态，最后的拒信居然没有外审意见，说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578795, encodeId=ead55e87956f, content=再等等看吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝硬化;预测模型 经验分享：肝病4大顶刊之一，有幸中了一篇。 贡献一个timeline； 07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit 5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投，现在修回去了，但是刚提交几个小时状态就变成了reviews returned，有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：回顾性临床研究 11.18投稿，12.2拒稿 附两个审稿人的审稿意见 编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=)]

2019-10-25 147612bem32暂无昵称

再等等看吧

211 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗？凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE，投稿一星期了，还是Selecting/Assigning Reviewers，困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投了一篇clinical trial 04/04/2019 Submission 04/05/2019 Selecting/Assigning Reviewers 04/08/2019 Under Review 04/09/2019 Selecting/Assigning Reviewers 04/09/2019 Under Review 04/22/2019 Reviews Returned 05/01/2019 Evaluating Reviews 05/02/2019 Reject with Transfer – HepComm 非常诡异的是，经历了一个月选审稿人又重选审稿人又under review的状态，最后的拒信居然没有外审意见，说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578795, encodeId=ead55e87956f, content=再等等看吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝硬化;预测模型 经验分享：肝病4大顶刊之一，有幸中了一篇。 贡献一个timeline； 07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit 5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投，现在修回去了，但是刚提交几个小时状态就变成了reviews returned，有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：回顾性临床研究 11.18投稿，12.2拒稿 附两个审稿人的审稿意见 编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=)]

2024-03-26 Charls.Guo 来自上海

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：肝硬化;预测模型
经验分享：肝病4大顶刊之一，有幸中了一篇。
贡献一个timeline；
07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit
5-Mar-2024 修回 - 24-Mar-2024 accept

10 0

[GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗？凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE，投稿一星期了，还是Selecting/Assigning Reviewers，困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投了一篇clinical trial 04/04/2019 Submission 04/05/2019 Selecting/Assigning Reviewers 04/08/2019 Under Review 04/09/2019 Selecting/Assigning Reviewers 04/09/2019 Under Review 04/22/2019 Reviews Returned 05/01/2019 Evaluating Reviews 05/02/2019 Reject with Transfer – HepComm 非常诡异的是，经历了一个月选审稿人又重选审稿人又under review的状态，最后的拒信居然没有外审意见，说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578795, encodeId=ead55e87956f, content=再等等看吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝硬化;预测模型 经验分享：肝病4大顶刊之一，有幸中了一篇。 贡献一个timeline； 07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit 5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投，现在修回去了，但是刚提交几个小时状态就变成了reviews returned，有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：回顾性临床研究 11.18投稿，12.2拒稿 附两个审稿人的审稿意见 编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=)]

2022-12-10 ms6000001750417887 来自北京

一审给了拒稿修改后重投，现在修回去了，但是刚提交几个小时状态就变成了reviews returned，有大佬知道这是为啥吗

95 0

[GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗？凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE，投稿一星期了，还是Selecting/Assigning Reviewers，困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投了一篇clinical trial 04/04/2019 Submission 04/05/2019 Selecting/Assigning Reviewers 04/08/2019 Under Review 04/09/2019 Selecting/Assigning Reviewers 04/09/2019 Under Review 04/22/2019 Reviews Returned 05/01/2019 Evaluating Reviews 05/02/2019 Reject with Transfer – HepComm 非常诡异的是，经历了一个月选审稿人又重选审稿人又under review的状态，最后的拒信居然没有外审意见，说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578795, encodeId=ead55e87956f, content=再等等看吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝硬化;预测模型 经验分享：肝病4大顶刊之一，有幸中了一篇。 贡献一个timeline； 07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit 5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投，现在修回去了，但是刚提交几个小时状态就变成了reviews returned，有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：回顾性临床研究 11.18投稿，12.2拒稿 附两个审稿人的审稿意见 编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=)]

2021-12-02 YJJJJJ

审稿速度:1.0 | 投稿命中率:5.0
经验分享：回顾性临床研究
11.18投稿，12.2拒稿
附两个审稿人的审稿意见
编辑建议转投hc

115 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务